The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of around 5.6% during the forecast period (2021-2027). The key factor to drive the market growth includesthe increasing prevalence of diabetes that results in increased chances of nephrotic syndrome. For instance, In the European Union, approximately 32.3 million adults were diagnosed with diabetes in 2019, up from an estimated 16.8 million adults in 2000. In 2019, it was estimated that around 24.2 million people in Europe will be having diabetes but will go undiagnosed.Since 2000, the number of men diagnosed with diabetes has more than doubled, rising from about 7.3 million in 2000 to 16.7 million in 2019. Women with diabetes have also increased significantly, from 9.5 million in 2000 to 15.6 million in 2019.
Browse the full report description of "Global Nephrotic Syndrome Diagnostics & Therapeutics Market Size, Share & Trends Analysis Report by Diagnosis Tests (Urinalysis, Blood Tests, Kidney Biopsy, and Others) By Treatment (Blood Pressure Lowering Medications, Immune System-Suppressing Medications, Cholesterol-Reducing Medications, and Others) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/nephrotic-syndrome-diagnostics-therapeutics-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in April 2019, Angion announced a partnership agreement with Nephrotic Syndrome Study Network (NEPTUNE)in order to investigate ANG-3070. This clinical research is based on understanding and treatment of kidney disorders.These findings of the research will supportdetermining the inclusion requirements for a biomarker stratified prospective clinical trial evaluating the safety and efficacy of ANG-3070 in primary Focal segmental glomerulosclerosis (FSGS) patients, ensuring that the most likely patients benefit from treatment.
Market Coverage
o By Diagnosis Test
o By Treatment
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Report Segment
By Diagnosis Tests
By Treatment
o Angiotensin-Converting Enzyme (ACE) Inhibitors
o Angiotensin Receptor Blockers (ARBs)
o Others (Renin Inhibitors and Benazepril)
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/nephrotic-syndrome-diagnostics-therapeutics-market